These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 3264091

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ, Krosnick JA, Rosenberg SA.
    J Immunol; 1989 Jan 15; 142(2):726-33. PubMed ID: 2783444
    [Abstract] [Full Text] [Related]

  • 3. Lymphokine-activated killer cell activity after cryopreservation.
    Schmidt-Wolf IG, Aihara M, Negrin RS, Blume KG, Chao NJ.
    J Immunol Methods; 1989 Dec 20; 125(1-2):185-9. PubMed ID: 2607152
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Differential effect of cryopreservation on natural killer cell and lymphokine-activated killer cell activities.
    Martí F, Miralles A, Peiró M, Amill B, de Dalmases C, Piñol G, Rueda F, García J.
    Transfusion; 1993 Aug 20; 33(8):651-5. PubMed ID: 8342231
    [Abstract] [Full Text] [Related]

  • 6. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M, Hasegawa H, Nakayabu M, Fukai K, Suzuki S.
    J Clin Lab Immunol; 1993 Aug 20; 40(2):47-60. PubMed ID: 7932628
    [Abstract] [Full Text] [Related]

  • 7. The influence of cryopreservation on activity and surface markers of lymphokine-activated killer cells.
    Letellier C, Rameliarison L, Fizet D, Ferrer AM, Vezon G.
    Vox Sang; 1991 Aug 20; 61(2):90-5. PubMed ID: 1763504
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
    Kalland T, Belfrage H, Bhiladvala P, Hedlund G.
    J Immunol; 1987 Jun 01; 138(11):3640-5. PubMed ID: 3495566
    [Abstract] [Full Text] [Related]

  • 10. Ewing's sarcoma: ex vivo sensitivity towards natural and lymphokine-activated killing.
    Atzpodien J, Gulati SC, Shimazaki C, Bührer C, Oz S, Kwon JH, Kolitz JE, Clarkson BD.
    Oncology; 1988 Jun 01; 45(6):437-43. PubMed ID: 3263598
    [Abstract] [Full Text] [Related]

  • 11. Phenotypic and functional analysis of lymphokine-activated killer (LAK) cell clones. Ability of CD3+, LAK cell clones to produce interferon-gamma and tumor necrosis factor upon stimulation with tumor targets.
    Chong AS, Aleksijevic A, Scuderi P, Hersh EM, Grimes WJ.
    Cancer Immunol Immunother; 1989 Jun 01; 29(4):270-8. PubMed ID: 2502310
    [Abstract] [Full Text] [Related]

  • 12. Differential effects of recombinant interferons alpha, beta, and gamma on induction of human lymphokine (IL-2)-activated killer activity.
    Sone S, Utsugi T, Nii A, Ogura T.
    J Natl Cancer Inst; 1988 May 18; 80(6):425-31. PubMed ID: 3130488
    [Abstract] [Full Text] [Related]

  • 13. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
    Muralikrishna K, Varalakshmi C, Khar A.
    Cytokines Cell Mol Ther; 1997 Mar 18; 3(1):51-8. PubMed ID: 9287244
    [Abstract] [Full Text] [Related]

  • 14. Interleukin-2 modulates the expression of lymphocyte function-associated antigen-one (LFA-1) and p150,95 during the generation of lymphokine-activated killer (LAK) cells.
    Grant AJ, Merchant RE, Hall RE.
    Immunology; 1989 Jan 18; 66(1):117-24. PubMed ID: 15493273
    [Abstract] [Full Text] [Related]

  • 15. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers.
    Nio Y, Zighelboim J, Berek JS, Bonavida B.
    Nat Immun Cell Growth Regul; 1990 Jan 18; 9(4):283-96. PubMed ID: 2215516
    [Abstract] [Full Text] [Related]

  • 16. A functional and phenotypic comparison of murine natural killer (NK) cells and lymphokine-activated killer (LAK) cells.
    Hoskin DW, Stankova J, Anderson SK, Roder JC.
    Int J Cancer; 1989 May 15; 43(5):940-8. PubMed ID: 2469657
    [Abstract] [Full Text] [Related]

  • 17. [Low susceptibility of choriocarcinoma cell lines to lymphokine activated killer (LAK) cells].
    Kameda T, Negoro T, Hagiwara M, Koyama M, Matsuzaki N, Saji F, Tanizawa O.
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Jan 15; 41(1):1-6. PubMed ID: 2784473
    [Abstract] [Full Text] [Related]

  • 18. Human recombinant IL-4 suppresses the induction of human IL-2 induced lymphokine activated killer (LAK) activity.
    Brooks B, Rees RC.
    Clin Exp Immunol; 1988 Nov 15; 74(2):162-5. PubMed ID: 3265652
    [Abstract] [Full Text] [Related]

  • 19. Target cell-directed inactivation and IL-2-dependent reactivation of LAK cells.
    Xiao J, Brahmi Z.
    Cell Immunol; 1989 Sep 15; 122(2):295-306. PubMed ID: 2788512
    [Abstract] [Full Text] [Related]

  • 20. Interleukin 2 induces human acute lymphocytic leukemia cells to manifest lymphokine-activated-killer (LAK) cytotoxicity.
    Kaufmann Y, Levanon M, Davidsohn J, Ramot B.
    J Immunol; 1987 Aug 01; 139(3):977-82. PubMed ID: 3496395
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.